Control of Human Mesothelin-expressing Tumors By DNA Vaccines

Abstract (Set) Mesothelin has been implicated as a potential ideal target antigen for the development of antigen-specific cancer immunotherapy for the control of mesothelin-expressing cancers such as ovarian cancer, mesothelioma, and pancreatic adenocarcinoma. JHU researchers utilized a DNA vaccine encoding human mesothelin to treat mice challenged with luciferase-expressing human mesothelin-expressing ovarian cancer cell line, Defb29 Vegf-Iuc/Hmeso. The therapeutic effect of the tumor challenged mice was followed by non-invasive bioluminescence imaging systems. The mechanism of the anti-tumor effect was characterized by depletion of subsets of lymphocytes as well as adopted transfer of serum from the vaccinated mice. They found that vaccination with the mesothelin DNA vaccine generates a significant anti-tumor effect and promotes survival in mice challenged with Defb29Vegf-Iuc/Hmeso. Furthermore, they found that CD4+ and CD8+ T cell immune responses, as well as the humoral immune responses, are important for the observed anti-tumor effects in vaccinated mice. Description (Set) Proposed Use (Set) Vaccination with DNA vaccine targeting human mesothelin could generate potent antitumor effects against mesothelin-expressing tumors through both T cell-mediated immunity as well as antibody-mediated immunity.

Inventor(s): Hung, Chien-Fu ,Wu, T.C.

Type of Offer: Licensing

Next Patent »
« More Medical Patents

Share on      

CrowdSell Your Patent